BioCentury | May 25, 2015
Clinical News

IV ALD403: Additional Phase Ib data

...migraine. Also next half, the company plans to start a Phase IIb dose-ranging trial of subcutaneous ALD403...
BioCentury | May 9, 2015
Company News

Alder fleshes out timeline for migraine candidate

...designed for self-administration. Alder expects top-line data next half from a Phase I trial of subcutaneous ALD403...
...administered quarterly. The company plans to begin a Phase IIb dose-ranging trial next half of subcutaneous ALD403...
BioCentury | Jan 9, 2015
Financial News

Funding roundup: Alder, Avalanche, OvaScience, Stemline

...An IV formulation of ALD403 is in a Phase IIb trial for chronic migraine, with subcutaneous ALD403...
BioCentury | May 14, 2012
Clinical News

ALD403: Phase I started

...Alder began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of IV and subcutaneous ALD403...
Items per page:
1 - 4 of 4